Zealand Pharma A/S (LON:0NZU)

Market Cap	4.06B
Revenue (ttm)	1.07B
Net Income (ttm)	764.70M
Shares Out	n/a
EPS (ttm)	10.71
PE Ratio	5.31
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,202
Average Volume	27,686
Open	494.85
Previous Close	491.54
Day's Range	491.60 - 507.00
52-Week Range	307.10 - 814.50
Beta	n/a
RSI	49.50
Earnings Date	Nov 13, 2025

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 335
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0NZU

Financial Performance

In 2024, Zealand Pharma's revenue was 62.69 million, a decrease of -81.71% compared to the previous year's 342.79 million. Losses were -1.08 billion, 53.3% more than in 2023.

Financial numbers in DKK